Bladder Cancer
Durvalumab granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer
February 17, 2016
Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma
February 17, 2016
David J. McConkey, Ph.D., Named Director of the Johns Hopkins Greenberg Bladder Cancer Institute
February 16, 2016
A Review Comparing Experience and Results with Bipolar Versus Monopolar Resection for Treatment of Bladder Tumors
February 16, 2016
Oncologic surveillance in bladder cancer following radical cystectomy: A systematic review and meta-analysis
February 16, 2016
Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients
February 16, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
February 15, 2016
Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer
February 15, 2016
A chronic care ostomy self-management program for cancer survivors
February 12, 2016
Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems
February 12, 2016
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
February 12, 2016
Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
February 11, 2016
EMERGING IMMUNOTARGETS IN BLADDER CANCER
February 11, 2016
Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World
February 11, 2016
Diabetes is an Important Risk Factor for Metastasis in Non- Muscle-Invasive Bladder Cancer
February 11, 2016